Claritas Pharmaceuticals Inc CLAZF

Healthcare Biotechnology

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

GREY:CLAZF - Post by User

Claritas Pharmaceuticals Inc > Buyout

<< Previous

Bullboard Posts

Next >>

Comment by 011Pekingon Apr 27, 2021 8:37am

136 Views

Post# 33073041

RE:Re: Buyout

Sounds pretty interesting! Could someone explain how a buyout benefits ut as shareholders? Say we get bought out today when we're at 0.05. How much would we get for each share? Of course nobody knows for sure but someone may have a clue? Would we get as it is. 0.05 or x2, x10 etc?

<< Previous

Bullboard Posts

Next >>

Cizzle Brands, Changing Consumer Habits in Consumables